In contrast, combined treatment with anti‐PD1 and anti‐CSF1R antibodies induces tumour regression in all mice and prolongs their survival.44 These results indicate that the TAM depletion by targeting CCR2 and/or CSF1R can improve the efficacy of checkpoint inhibitors (Fig. 2b). Here, PDCD1 is linked to neoplasm.